Top

News & Events

Archive: 2017

News Archive

European Mediscience Awards Dinner 2017

15 June 2017
European Mediscience Awards 2017
London, UK

Table Host: Melanie Toyne Sewell

Read more »

BioEquity Europe

22 - 23 May 2017
BioEquity Europe
Paris, France

Read more »

biotrinity 2017

8 – 10 May 2017
Biotrinity 2017
London, UK

Read more »

BIA Networking Breakfast - London

20 April 2017
BIA Networking Breakfast - London
London, UK

Read more »

Clinigen hosts Unlicensed Medicines satellite symposium at 22nd Congress of EAHP

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, announces that its Idis GA division is holding a satellite symposium today on Access to Unlicensed Medicines as part of the 22nd Congress of European Association of Hospital Pharmacists (EAHP), taking place in Cannes, France.

Read more »

SkinBioTherapeutics intention to launch Initial Public Offering and list on AIM

Manchester, UK - SkinBioTherapeutics plc (“SkinBio” or the “Company”), a life science company focused on skin health, intends to seek Admission to AIM with an associated institutional and private client fundraising.

Read more »

European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint® Test with Highest Level 1A Clinical Evidence

Irvine, CA, USA and Amsterdam, the Netherlands - Agendia, a world leader in personalized medicine and molecular cancer diagnostics, announces that updated guidelines from the European Group on Tumour Markers (EGTM), published recently online in the European Journal of Cancer (EJC), name the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence test as the first and currently the only multigene test of its kind deemed to have level 1A evidence for its clinical use.1

Read more »

AdAlta expands partnership with world-leading fibrosis research team at Melbourne’s The Alfred Hospital

MELBOURNE Australia: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development today announced the continuation of its collaboration with The Alfred hospital in Melbourne, Australia, and the clinical research team led by Dr Glen Westall, an expert in lung fibrosis and Idiopathic Pulmonary Fibrosis (IPF).

Read more »

Auspherix to Present Organogold Pipeline at Superbugs & Superdrugs

Stevenage, UK – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, is pleased to announce that it has been invited to present at this year’s Superbugs & Superdrugs conference in London, 20-21 March 2017.

Read more »

Mission Therapeutics Strengthens Senior Leadership Team with the Appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research

Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announced the appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research, effective 20 March 2017.

Read more »

BIA Networking Breakfast – Manchester

16 March 2017
BIA Networking Breakfast – Manchester
Alderley Park, UK

Read more »

Cell Medica: £60 million Series C financing to advance multiple cancer programmes

London, UK – Cell Medica (or ‘the Company’), a leading cellular immunotherapy company, has closed a £60 million Series C investment round with participation from existing investors Touchstone Innovations, funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management.

Read more »

Innovations invests £13.7m in £60.0m funding round in Cell Medica

Touchstone Innovations plc (AIM: IVO, ‘the Group’, ‘Innovations’) has participated in a £60.0m funding round in Cell Medica Limited (“Cell Medica” or “the Company”) committing £13.7 million to the round alongside co-investors Invesco Asset Management and Woodford Investment Management.

Read more »

Clinigen and Diurnal partner for European Managed Access programme for Infacort® and Chronocort®

Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Diurnal Group plc (AIM: DNL, ‘Diurnal’), have partnered to launch a Managed Access programme in Europe for Infacort® to treat paediatric patients with adrenal insufficiency (AI) and Chronocort® to treat patients with congenital adrenal hyperplasia (CAH).

Read more »

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

Nijmegen, The Netherlands – On 9 February 2017, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (USPTO) denied institution of Forty Seven Inc.’s petitions for inter partes review of the US 9,352,037 patent which was issued in May 2016.

Read more »

Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

Stevenage, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £895,000 from the Biomedical Catalyst for initiation of a research programme with a novel approach to the treatment of dementia. An investment of £400,000 from the Dementia Discovery Fund (“DDF”) will also be used to pursue this highly novel approach to dementia treatment.

Read more »

Clinigen Group plc: STRONG H1 PERFORMANCE WITH ADJUSTED EPS UP 31%*

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services company, today publishes its half year results for the six months ended 31 December 2016.

Read more »

Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

Cambridge, UK – Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received US Food and Drug Administration (FDA) marketing approval for Kisqali® (ribociclib, formerly known as LEE011) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced (metastatic) breast cancer.

Read more »

First-in-class Fycompa® (perampanel) approved in South Africa for partial-onset seizures

Clinigen Group plc - Eisai is pleased to announce that perampanel has been approved in South Africa for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.1 Perampanel is the first anti-epileptic drug to be approved in South Africa in recent years.

Read more »

German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence

Irvine, CA, USA and Amsterdam, the Netherlands - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the company’s MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence test is now included with the highest medical evidence level 1A in the latest version of AGO (German Association of Gynecological Oncology) guidelines for the care of breast cancer patients in Germany.

Read more »

SACHS 10th Annual European Life Sciences CEO Forum & Exhibition

6 – 7 March 2017
10th Annual European Life Sciences CEO Forum & Exhibition
Zurich, Switzerland

Read more »

DNAe Appoints International Infectious Disease Experts to its Newly Formed Clinical Advisory Board

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the formation of its clinical advisory board (CAB). The CAB, with founding members Professor Paul Dark, Professor Angela Caliendo, Professor Stephan Harbarth and Professor Romney Humphries, brings together US and European experts to provide strategic guidance for the clinical development of DNAe’s diagnostic platform, LiDia™, and its accompanying range of tests for different clinical applications.

Read more »

‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase II clinical trial.

Read more »

Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and Development. The appointment is effective from today.

Read more »

Staten Biotechnology exercises option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia from argenx N.V.

Nijmegen, The Netherlands – Staten Biotechnology, a company focused on the treatment of dyslipidemia and reduction of cardiovascular mortality today announced that it has exercised an exclusive option to license ARGX-116 (STT-5058), an anti-ApoC3 SIMPLE Antibody from argenx N.V.

Read more »

One Nucleus: Leadership Seminar: Microbiome – Research to Revenue

2 March 2017
One Nucleus: Leadership Seminar: Microbiome – Research to Revenue
Norwich Research Park, UK

Read more »

Synthon enters worldwide exclusive license and collaboration with Sanquin for immuno-oncology therapeutic leads modulating the CD47-SIRPα pathway

Nijmegen and Amsterdam, The Netherlands - Synthon Biopharmaceuticals BV, an international biopharmaceutical company that is focused on developing new molecular entities for treating cancer and autoimmune diseases, today announced that it has entered a license and collaboration agreement for the development of novel immuno-oncology antibodies with Sanquin Blood Supply Foundation (‘Sanquin’), Amsterdam.

Read more »

Abzena plc: Medical Research Council grant awarded to collaboration group developing novel autoimmune therapy

Cambridge and London, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products and UCL (University College London), one of the world’s leading multidisciplinary universities, supported by UCL Business, the technology commercialisation company of UCL, announce that a research group from UCL’s Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to progress the development of a novel treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.

Read more »

Whatman™ EasiCollect™+ System for simple, reliable buccal sample collection and storage

EasiCollect™ + System from GE Healthcare’s Life Sciences business addresses the difficulties of buccal cell collection for forensic analysis with an updated design which increases usability and first pass success rates. Providing consistent sample transfer to FTA™ cards, EasiCollect+ simplifies the collection and storage of DNA for genetic analysis in forensics, human identification and SNP genotyping.

Read more »

Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs

LONDON, BOSTON, TOKYO  – The steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the EvaluatePharma Orphan Drug Report 2017. What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products.

Read more »

Halaven® (eribulin) launches in South Africa for the treatment of women with advanced breast cancer

Halaven® (eribulin) is now available in South Africa for the treatment of women with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for their advanced disease. Prior therapy should have included an anthracycline and a taxane, unless patients were not suitable for these treatments.

Read more »

Congenica raises £8M ($10M) in Series B financing round to drive international expansion of its genome analysis business

CAMBRIDGE, UK - Congenica, a leading provider of clinical genome analysis technology, announced today that it has raised £8m ($10m) in its Series B financing round. Existing investors, Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners (Amadeus) participated alongside new investor, Parkwalk Advisors (Parkwalk).

Read more »

Recce Releases Microscopy Images of its Synthetic Antibiotic in Action Destroying Bacteria

SYDNEY, Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotic, today released images taken of RECCE® 327 destroying Escherichia coli Gram-negative bacteria, the superbug form of which has been declared by the US Centres for Disease Control and Prevention as an urgent threat to world health.

Read more »

AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman

San Diego, U.S. – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board (SAB) and the appointment of Timothy K. Lu, M.D., Ph.D., as Chairman of the SAB. Dr. Lu heads the Massachusetts Institute of Technology’s (MIT) Synthetic Biology Group in the Research Laboratory of Electronics, where he applies proprietary engineering techniques to biological systems, including bacteriophages, to address global concerns such as the growing incidence of antibiotic resistance.

Read more »

20 years ago Instinctif Partner’s Sue Charles introduced a now famous sheep to the world

On this Day - 22 Feb 1997

20 years ago Instinctif Partner’s Sue Charles introduced a now famous sheep to the world

In February 1997, via a publication in Nature, scientists in Scotland announced the birth of the world's first successfully cloned mammal, and it was Instinctif Partners Managing Partner Sue Charles, who led the PR effort to introduce ‘Dolly the sheep’ to the world.

Read more »

Recce to suspend anti-cancer program and focus on commercialising synthetic lead compound against resistant bacteria and viruses

SYDNEY, Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of antibiotics, today announced it would halt further investment in its anti-cancer program and focus on commercialising its lead synthetic compound RECCE® 327 to address drug resistant bacteria and viruses.

Read more »

Funding of four initial projects and operational update

Stevenage: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, has invested in and launched the first of its drug discovery programmes in collaboration with academics at each of its partner universities.

Read more »

DNAe announces opening of US facility, expansion of operations and launches product brand as it prepares for commercialization

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the opening of its new US facility in preparation for commercializing its first product. DNAe also announces its new brand identity.

Read more »

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016

LONDON, BOSTON, SAN FRANCISCO, TOKYO – For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released today as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.

Read more »

Innovations portfolio company Cell Medica granted FDA Fast Track designation for lead oncology product

Touchstone Innovations plc (AIM: IVO, ‘the Group’, ‘Innovations’) is pleased to note today’s announcement by portfolio company Cell Medica (the ‘Company’) that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead oncology product (CMD-003) for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein Barr virus (EBV).

Read more »

Lead cancer immunotherapy candidate receives FDA fast track designation

London, UK and Houston, TX, US - Cell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product CMD-003 for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein Barr virus (EBV).

Read more »

Abzena plc: Antibody manufacturing development agreement signed with UCL

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a manufacturing agreement with University College London (‘UCL’), one of the world’s leading universities. Under the agreement, Abzena will manufacture Magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody™ technology.

Read more »

Abzena plc: Trading and business update

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides the following business update for the period to 20 February 2017.

Read more »

Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

Groningen, The Netherlands – Polyganics, a privately held medical technology company, announced today that interim results show a sharp improvement in pain reduction observed across patients currently enrolled within the “STOP NEUROMA” study.

Read more »

Asthma UK’s ‘Smart Asthma’ report highlights opportunity to improve asthma care through connected health

Melbourne, Australia - Adherium Limited (ASX: ADR, ‘Adherium’), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, welcomes the recommendations highlighted in Asthma UK’s report on the use of connected devices in managing asthma, published today. ‘Smart Asthma for the UK; Real world implementation of connected devices to reduce asthma attacks’, highlights the opportunities for healthcare providers to positively influence clinical and economic outcomes for asthma care in the UK through the use of connected devices and improved technology infrastructure.

Read more »

Trod Medical Receives US Patent Allowance for Prostate Focal Therapy EncageTM Device

Leuven, Belgium – Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office (USPTO), entitled  “Method of percutaneous localized or focal treatment of prostate lesions using radio frequency”, with patent ID US 20110288541 A1.

Read more »

Biotech and Money London 2017

7 – 8 February 2017
Biotech and Money London
London, UK

Read more »

Forbion Invests in Prexton Therapeutics’ EUR 29 million (USD 31 million) Series B Financing

Naarden, The Netherlands – Forbion Capital Partners (“Forbion”), one of the leading Dutch Venture Capital firms investing in world-class healthcare technologies, today announced the closing of a Series B financing round of EUR 29 million (USD 31 million) for Prexton Therapeutics (Prexton). Prexton is a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions.

Read more »

Atomo Diagnostics receives further international financing

SYDNEY, Australia: Medical device innovator Atomo Diagnostics today announced it had received US$1 million (A$1.31 million, C$1.32 million) in financing from Grand Challenges Canada to support its continued business operations.

Read more »

Ampliphi Biosciences to Present at the 19th Annual BIO CEO and Investor Conference

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that CEO M. Scott Salka will present a company overview at the 19th Annual BIO CEO and Investor Conference on Monday, February 13, 2017 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time).  The conference is being held at the Waldorf Astoria New York hotel in New York City.

Read more »

UV-Cap GmbH & Co KG acquires Scil Proteins GmbH Scil Proteins GmbH becomes Navigo Proteins GmbH

Halle (Saale), Germany – Scil Proteins GmbH, the expert protein engineering company for affinity ligands and targeted carriers, today announced that UV-Cap GmbH & Co KG, Ravensburg, has acquired 100% of the shares of Scil Proteins from Bionet Ventures GmbH, Munich. The Company will be renamed to Navigo Proteins GmbH. All staff and management will be retained.

Read more »

Arven Pharmaceuticals selects GE Healthcare’s FlexFactory to improve Turkish and regional access to biopharmaceuticals

CHALFONT ST. GILES, UK and ISTANBUL, TURKEY – Arven Pharmaceuticals, a Toksoz Group Company, has selected GE Healthcare’s FlexFactory manufacturing platform to expand production capacity at its facility in Kirklareli, Turkey. With this expanded capacity, Arven will support local healthcare needs by bringing biopharmaceuticals to the Turkish and surrounding markets faster, whilst also opening up European markets through the FlexFactory’s proven track record in meeting global regulations and quality standards.

Read more »

Dimerix key patent allowed in Japan for use of lead drug candidate in the treatment of kidney disease

MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced the Japanese Patent Office has allowed a key patent covering the use of its lead compound DMX-200 for the treatment of kidney disease.

Read more »

AdAlta’s Q4 Statement – Delivering on Key Milestones and Progress of AD-114 Lead Fibrosis Product Towards the Clinic

AdAlta continues to meet its commercial and development milestones and is making excellent progress towards its stated goal of initiating Phase I human clinical trials for its lead candidate AD-114 as a therapy for the unmet medical need of idiopathic pulmonary fibrosis (IPF), including securing Orphan Drug Designation from the FDA. The Company is also developing AD-114 for Non-alcoholic steatohepatitis (NASH), a pandemic, metabolic disease which has both inflammatory and fibrotic components.

Read more »

AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the appointment of Igor P. Bilinsky, Ph.D., as its Senior Vice President and Chief Operating Officer, effective January 30, 2017.  Dr. Bilinsky brings to AmpliPhi nearly two decades of experience as a life sciences company executive and consultant, serving public and private companies.  He succeeds Wendy S. Johnson, who served as AmpliPhi’s interim COO since September 2014 and continues to serve on AmpliPhi’s board of directors.

Read more »

Agendia Co-Founder Laura van ‘t Veer Wins European Cancer Organization Clinical Research Award

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, congratulates its co-founder and Chief Research Officer, Professor Laura van ‘t Veer, Ph.D., on winning the European Cancer Organization’s (ECCO) Clinical Research Award for innovation in breast cancer diagnosis, and the development of diagnostics for implementation in daily clinical practice, including treatment guidelines, regulatory policies and reimbursement.

Read more »

BIA Gala Dinner 2017

26 January 2017
BIA Gala Dinner
London, UK

Read more »

Innovative Wellbeing Company Skinjay Receives €3.5M from Seventure Partner’s Health for Life Capital

Paris, France - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that from its Health for Life Capital investment vehicle it has invested €3.5 million in Skinjay.

Read more »

Evaluate: The Value of Outliers in Consensus Forecasting

LONDON, BOSTON, SAN FRANCISCO, TOKYO – Life science market intelligence firm Evaluate Ltd today released the first of a series of reports focused on Forecasting Excellence with an aim to improve the ability of the pharmaceutical industry to deploy capital more efficiently.

Read more »

Dimerix Raises AU$2 million to Advance Clinical Program

Dimerix Limited (“Dimerix” or “the Company”) advises that it has received commitments for a placement to raise AU$2,000,000 (before costs) (Placement). 333,333,333 new shares will be issued to sophisticated and professional investors under the Placement at an issue price of AU$0.006 per share. Westar Capital Ltd acted as Lead Manager to the offer.

Read more »

HY trading update: strong H1 performance with gross profit up 34%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides a trading update for the six months ended 31 December 2016.

Read more »

Abzena signs new ThioBridge™ licence agreement

Cambridge, UK – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement with a San Diego-based biopharmaceutical company for Abzena’s novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology.

Read more »

AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease

MELBOURNE Australia - AdAlta Limited (ASX: 1AD), today announced it has received Orphan Drug Designation from the United States Food and Drug Administration (FDA) for AD-114, a novel first-in-class drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF).

Read more »

Recce’s lead compound reduces illness in mice infected by resistant E. coli bacteria

SYDNEY: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics to treat serious infections, today announced encouraging early results for the company's lead product candidate RECCE® 327 as a potential treatment against Carbapenem resistant Gram-negative (CRE) Escherichia coli (CRE E. coli).

Read more »

Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance

Joins trade associations and over 100 pharmaceutical, biotech and diagnostic companies to call for collective action and government support to tackle crisis

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections, has signed The Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR), announced today at the World Economic Forum Annual Meeting in Davos, Switzerland.
 

Read more »

Clinigen initiates U.S. Managed Access program for TESARO’s niraparib for patients with ovarian cancer

Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access (MA) division has partnered with TESARO Inc. (NASDAQ: TSRO), to launch a Managed Access program (also known as an expanded access program (EAP)) for the investigational PARP 1/2 inhibitor, niraparib.

Read more »

35th J.P. Morgan Healthcare Conference & 9th Annual Biotech Showcase

9 – 11 January 2017
35th J.P. Morgan Healthcare Conference & 9th Annual Biotech Showcase
San Francisco, US

Read more »

Instinctif Partners awarded silver in the PR Week UK Best Places to Work Awards 2017

Instinctif Partners has been awarded silver in the large consultancy category by PR Week for Best Places to Work

These awards recognise those UK-based consultancies and in-house comms departments that go the extra mile to offer a superb working environment and progressive practices in the workplace, whether it's around training, mentoring, pay, maternity and paternity issues, or a host of other areas.

Read more »

NICE acknowledges Smartinhaler™ technology can improve adherence to asthma medication

NICE (the National Institute for Clinical Excellence) has today issued a Medtech Innovation Briefing on Smartinhaler™, Adherium Limited’s (ASX: ADR) innovative digital inhaler technology platform, which has been proven to increase patient adherence to asthma medication, reduce hospital visits and time needed off school or work over the current standard care.

Read more »

Adherium appoints digital health pioneer to lead European business development

Digital health veteran to join expanding global team

Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. John Tarplee stepped down from the role at the end of December 2016 to pursue a new venture.

Read more »

Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

Demonstrated dose dependent changes in Mismatch Negativity latency in healthy volunteers; Phase Ib Ketamine challenge study initiated in Manchester.

London, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced positive findings from a Phase Ia clinical trial of AUT00206, a first-in-class Kv3 modulator in development for the treatment of schizophrenia, as well as the start of the first of two Phase Ib studies with the molecule.

Read more »

Clinigen and Cumberland Pharmaceuticals enter exclusive U.S. commercialisation agreement for Totect®

Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a U.S. specialty pharmaceutical company announce an exclusive agreement to commercialise the oncology support drug, Totect® (dexrazoxane hydrochloride) in the U.S.

Read more »

Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave® as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections

Vienna, Austria - Hookipa Biotech AG, an immunotherapy company developing next-generation cancer immune therapeutics and vaccines based on the Company's proprietary arenavirus vector platforms, announces publication in the January 2017 issue of the peer-reviewed journal Clinical and Vaccine Immunology, of data confirming the potential of Hookipa’s HB-101 Vaxwave® to provide an effective and novel bivalent vaccine that confers better protection against congenital (maternal transmission) cytomegalovirus infection in the gold standard animal model, the guinea pig model, in reducing pup mortality.

Read more »

AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential

MELBOURNE Australia, 9 January, 2017 - AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development today announced additional positive pre-clinical data for its lead drug candidate AD-114, a novel first-in-class drug candidate being developed to treat fibrosis, a condition prevalent in 45 to 50 per cent of all diseases.

Read more »

Appointment of Amgen Executive Director as Chief Executive

Oxford, UK – e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it has appointed Dr. Raymond Barlow as Chief Executive Officer. Dr. Barlow will take up the role on or before 1 May 2017, at which point he will be appointed to the e-Therapeutics Board of Directors.

Read more »

Seventure Partners Life Sciences, Microbiome Investing: Update for September – December 2016

Paris, France – Seventure Partners (the Company), one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for September – December 2016.

Read more »

Auspherix Provides Update on its New Class of Organogold Antibiotics

Stevenage, UK – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today provided an update on its organogold chemistry platform and its pipeline of compounds.

Read more »

Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies

Santa Monica, CA and Alachua, FL – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis.

Read more »

Xigen’s Brimapitide, an innovative JNK inhibitor, delivers positive Phase II results in inflammatory eye disease

Geneva, Switzerland – Xigen, a Swiss Company developing therapeutic peptides for the treatment of inflammatory diseases announces today the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology.

Read more »

Change of name to Touchstone Innovations plc and change of registered office

Imperial Innovations Group plc (AIM: IVO, ‘the Company’) announces that further to the shareholder approval received at its AGM on 21 November 2016, the change of the Company's  name to Touchstone Innovations plc took effect on 4 January 2017.

Read more »

Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Peter-John Wormald, MD, Professor of Otolaryngology Head & Neck Surgery at the University of Adelaide, commented on the favorable results from the Phase 1 trial of AmpliPhi’s AB-SA01 in patients with chronic rhinosinusitis (CRS).

Read more »

Clinical Network Services (CNS) UK Announces the Appointment of Dr Martin Moxham as Principal Regulatory Consultant

Brisbane, Australia - Clinical Network Services (CNS), an integrated service group focused on clinical product development and headquartered in Australia with offices in New Zealand, the UK and the USA, has announced the appointment of Martin Moxham as Principal Regulatory Consultant for Europe from 1 January 2017.

Read more »